Trial Profile

A first-in-human Phase 1 clinical trial of APTN-101 program in glioblastoma (GBM).

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APTN 101 (Primary)
Indications Glioblastoma; Glioma
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

15 Apr 2025 According to an Adaptin Bio media release, company believe financing, in connection with Adaptin eventual listing on the OTC, will enable company to nitiate our first-in-human Phase 1 clinical trial to evaluate APTN-101.
06 Sep 2024 According to an Adaptin Bio media release, company announced that the FDA has cleared an Investigational New Drug (IND) application for APTN-101 program in glioblastoma (GBM). The clearance will enable the initiation of a first-in-human Phase 1 clinical trial to evaluate this investigational candidate in GBM.
06 Sep 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com